Varex Imaging Reports Q4 Results and Focuses on Innovation Amid Revenue Decline

Varex Imaging Reports Financial Results Amid Technological Advancements

Varex Imaging Corporation has unveiled its unaudited financial results for the fourth quarter and fiscal year 2024, revealing important insights into its operational performance and strategic direction. The company reports revenues of $206 million for Q4 and $811 million for the entire fiscal year, marking a year-over-year decline of 10% in Q4 revenues. Notably, the medical segment, which contributes significantly to Varex’s overall performance, generated $144 million, reflecting a decrease of 12%. Despite these challenges, Varex continues to prioritize innovation and market expansion, particularly within its industrial segment, which has shown resilience during this fiscal period.

CEO Sunny Sanyal emphasizes the company's commitment to technological advancement, highlighting recent developments in innovative imaging technologies. Varex's focus on expanding its offerings into the cargo systems vertical signifies a strategic move to diversify its revenue streams. The industrial segment's performance has been a bright spot for the company, helping offset the downturn in the medical segment. As Varex navigates a competitive landscape, the leadership remains optimistic about leveraging their technological capabilities to capture new market opportunities and drive future growth.

In financial metrics, Varex reports a GAAP gross margin of 33% for Q4 and 32% for the fiscal year, consistent with non-GAAP figures. The company also reports operating expenses of $56 million for Q4, with operating margins at 5% (GAAP) and 7% (non-GAAP). While Varex faces a net loss of $(1.22) per diluted share in Q4, the non-GAAP net earnings show a more favorable picture at $0.19 per diluted share. The firm concludes the fiscal year with a robust cash position, reporting $213 million in cash and marketable securities, bolstering its financial stability as it looks ahead to future initiatives.

In its forward-looking guidance for Q1 FY25, Varex projects revenues between $195 million and $215 million, with anticipated non-GAAP net earnings per diluted share ranging from -$0.05 to $0.10. While the company confronts headwinds from a declining medical segment, its strong balance sheet and focus on innovation position it well for potential recovery and growth in the upcoming quarters. As Varex continues to evolve, its ability to adapt to changing market dynamics and technological demands will be critical for its sustained success in the imaging industry.